Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer's Disease
- PMID: 40913038
- PMCID: PMC12413461
- DOI: 10.1038/s41467-025-63564-2
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer's Disease
Abstract
The distribution of tau pathology in Alzheimer's disease (AD) shows remarkable inter-individual heterogeneity, including hemispheric asymmetry. However, the factors driving this asymmetry remain poorly understood. Here we explore whether tau asymmetry is linked to i) reduced inter-hemispheric brain connectivity (potentially restricting tau spread), or ii) asymmetry in amyloid-beta (Aβ) distribution (indicating greater hemisphere-specific vulnerability to AD pathology). We include 452 participants from the Swedish BioFINDER-2 cohort with evidence of both Aβ pathology (CSF Aβ42/40 or neocortical Aβ-PET) and tau pathology (temporal tau-PET), categorising them as left asymmetric (n = 102), symmetric (n = 306), or right asymmetric (n = 44) based on temporal lobe tau-PET uptake distribution. We assess edge-wise inter-hemispheric functional (RSfMRI; n = 318) and structural connectivity (dMRI; n = 352) but find no association between tau asymmetry and connectivity. In contrast, we observe a strong association between tau and Aβ laterality patterns based on PET uptake (n = 233; β = 0.632, p < 0.001), which we replicate in three independent cohorts (n = 234; β = 0.535, p < 0.001). In a longitudinal Aβ-positive sample, we show that baseline Aβ asymmetry predicts progression of tau laterality over time (n = 289; β = 0.025, p = 0.028). These findings suggest that tau asymmetry is not associated with a weaker inter-hemispheric connectivity but might reflect hemispheric differences in vulnerability to Aβ pathology, underscoring the role of regional vulnerability in determining the distribution of AD pathology.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: O.H. is an employee of Eli Lilly and Lund University. R.S. has received consultancy/speaker fees from Eli Lilly, Novo Nordisk, Roche and Triolab. S.P. has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Esai, Eli Lilly, Novo Nordisk, and Roche. N.M.C. has received consultancy/speaker fees from Biogen, Eli Lilly, Owkin, and Merck. The precursor of [18F]flutemetamol was sponsored by GE Healthcare. The other authors declare no competing interests.
Figures
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
